Novel Solid Lipid Nanoparticles for Oral Delivery of Oxyresveratrol: Effect of the Formulation Parameters on the Physicochemical Properties and in vitro Release

Authors: Y. Sangsen, K. Likhitwitayawuid, B. Sritularak, K. Wiwattanawongsa, R. Wiwattanapatapee

Abstract:

Novel solid lipid nanoparticles (SLNs) were developed to improve oral bioavailability of oxyresveratrol (OXY). The SLNs were prepared by a high speed homogenization technique, at an effective speed and time, using Compritol^® 888 ATO (5% w/w) as the solid lipid. The appropriate weight proportions (0.3% w/w) of OXY affected the physicochemical properties of blank SLNs. The effects of surfactant types on the properties of the formulations such as particle size and entrapment efficacy were also investigated. Conclusively, Tween 80 combined with soy lecithin was the most appropriate surfactant to stabilize OXY-loaded SLNs. The mean particle size of the optimized formulation was 134.40 ± 0.57 nm. In vitro drug release study, the selected S2 formulation showed a retarded release profile for OXY with no initial burst release compared to OXY suspension in the simulated gastrointestinal fluids. Therefore, these SLNs could provide a suitable system to develop for the oral OXY delivery.

Keywords: Solid lipid nanoparticles, Physicochemical properties, in vitro drug release, Oxyresveratrol.

Digital Object Identifier (DOI): doi.org/10.5281/zenodo.1089465

References:

[1] K. Likhitwitayawuid, et al., "Phenolics with antiviral activity from Millettiaery throcalyx and Artocarpus lakoocha,” Nat. Prod. Res., vol. 19, no. 2, pp. 177–182, Feb. 2005.
[2] K. O. Chung, et al., "In-vitro and in-vivo anti-inflammatory effect of oxyresveratrol from Morus alba L.,” J. Pharm. Pharmacol., vol. 55, no. 12, pp. 1695–1700, Dec. 2003.
[3] P. Lorenz, S. Roychowdhury, M. Engelmann, G. Wolf, and T. F. W. Horn, "Oxyresveratrol and resveratrol are potent antioxidants and free radical scavengers: effect on nitrosative and oxidative stress derived from microglial cells,” Nitric Oxide, vol. 9, no. 2, pp. 64–76, Sep. 2003.
[4] P. Tengamnuay, K. Pengrungruangwong, I. Pheansri, and K. Likhitwitayawuid, "Artocarpus lakoocha heartwood extract as a novel cosmetic ingredient: evaluation of the in vitro anti-tyrosinase and in vivo skin whitening activities,” Int. J. Cosmet. Sci., vol. 28, no. 4, pp. 269-276, Aug. 2006.
[5] J. T. Weber, et al., "Potential neuroprotective effects of oxyresveratrol against traumatic injury,” Eur. J. Pharmacol., vol. 680, no. 1, pp. 55-62, Apr. 2012.
[6] P. Sasivimolphan, et al., "Inhibitory activity of oxyresveratrol on wild-type and drug-resistant varicella-zoster virus replication in vitro,” Antivir. Res., vol. 84, no. 1, pp. 95-97, Oct. 2009.
[7] A. L. Liu, et al., "In vitro anti-influenza viral activities of stilbenoids from the lianas of Gnetum pendulum,” Planta. Med., vol. 76, no. 16, pp. 1874–1876, Nov. 2010.
[8] V. Lipipun, et al., "Topical cream-based oxyresveratrol in the treatment of cutaneous HSV-1 infection in mice,” Antivir. Res., vol. 91, no. 2, pp. 154-160, Aug. 2011.
[9] W. Wang, J. Qian, X. Wang, and A. Jia, "Anti-HIV-1 activities of extracts and phenolics from Smilax China L.,” School of Environmental and Biological Engineering, Nanjing University of Science and Technology, Nanjing, private communication, 2013.
[10] H. Huang, et al., "High performance liquid chromatographic method for the determination and pharmacokinetic studies of oxyresveratrol and resveratrol in rat plasma after oral administration of Smilax china extract,” Biomed. Chromatogr., vol. 22, no. 4, pp. 421-427, Dec. 2007.
[11] H. Huang, et al., "Identification of seven metabolites of oxyresveratrol in rat urine and bile using liquid chromatography/tandem mass spectrometry,” Biomed. Chromatogr., vol. 24, no. 4, pp. 426-432, Aug. 2010.
[12] M. Mei, et al., "In vitro pharmacokinetic characterization of Mulberroside A, the main polyhydroxylated stilbene in mulberry (Morus alba L.), and its bacterial metabolite oxyresveratrol in traditional oral use,” J. Agr. Food Chem., vol. 60, no. 9, pp. 2299-2308, Dec. 2012.
[13] R. H. Müller, K. Mäder, and S. Gohla, "Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art.” Eur. J. Pharm. Biopharm., vol. 50, no. 1, pp. 161–177, July 2000.
[14] S. Chakraborty, D. Shukla, and S. Singh, "Lipid – an emerging platform for oral delivery of drugs with poor bioavailability,” Eur. J. Pharm. Biopharm., vol. 73, no. 1, pp. 1–15, Sep. 2009.
[15] E. B. Souto, and R. H. Müller, "Lipid nanoparticles: effect on bioavailability and pharmacokinetic changes,” in Drug Delivery, 1st ed. vol. 197, M. Schäfer-Korting, Ed. New York: Springer-Verlag, 2010, pp. 115-141.
[16] W. Mehnert, and K. Mäder, "Solid lipid nanoparticles: production, characterization and applications,” Adv. Drug Deliv. Rev., vol. 47, no. 2, pp. 165–196, Apr. 2001.
[17] Y. Luo, D. Chen, L. Ren, X. Zhao, and J. Qin, "Solid lipid nanoparticles for enhancing vinpocetine's oral bioavailability,” J. Control. Release, vol. 114, no. 1, pp. 53-59, May 2006.
[18] A. J. Almeida, and E. Souto, "Solid lipid nanoparticles as a drug delivery system for peptides and proteins,” Adv. Drug Deliv. Rev., vol. 59, no. 6, pp. 478-490, July 2007.
[19] L. Hu, Q. Xing, J. Meng, and C. Shang, "Preparation and enhanced oral bioavailability of cryptotanshinone loaded solid lipid nanoparticles,” AAPS Pharm. Sci. Tech., vol. 11, no. 2, pp. 582-587, June 2010.
[20] V. Kakkar, S. Singh, D. Singla, and I. P. Kaur, "Exploring solid lipid nanoparticles to enhance the oral bioavailability of curcumin,” Mol. Nutr. Food Res., vol. 55, no. 3, pp. 495-503, Aug. 2010.
[21] E. H. Gokce, et al., "Resveratrol-loaded solid lipid nanoparticles versus nanostructured lipid carriers: evaluation of antioxidant potential for dermal applications,” Int. J. Nanomedicine, vol. 7, pp. 1841-1850, Apr. 2012
[22] A. R. Neves, M. Lúcio, S. Martins, J. L. C. Lima, and S. Reis, "Novel resveratrol nanodelivery systems based on lipid nanoparticles to enhance its oral bioavailability,” Int. J. Nanomedicine, vol. 8, pp. 177-187, Jan. 2013.
[23] R. Tiwari, and K. Pathak, "Nanostructured lipid carrier versus solid lipid nanoparticles of simvastatin: comparative analysis of characteristics, pharmacokinetics and tissue uptake,” Int. J. Pharm., vol. 415, no. 1, pp. 232-243, Aug. 2011.
[24] M. Gibaldi, and S. Feldman, "Mechanisms of surfactant effects on drug absorption,” J. Pharm. Sci., vol. 59, no. 5, pp. 579-89, May 1970.
[25] G. Wu, and K. Y. C. Lee, "Effects of poloxamer 188 on phospholipid monolayer morphology: an atomic force microscopy study,” Langmuir, vol. 25, no. 4, pp. 2133-2139, Jan. 2009.
[26] P. L. Ritger, and N. A. Peppas, "A simple equation for description of solute release I. Fickian and non-fickian release from non-swellable devices in the form of slabs, spheres, cylinders or discs,” J. Control. Rel., vol. 5, no. 1, pp. 23-36, June 1987.
[27] C. Y. Zhuang, et al., "Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability,” Int. J. Pharm., vol. 394, no. 1, pp. 179-185, July 2010.
[28] M. Trotta, F. Debernardi, and O. Caputo, "Preparation of solid lipid nanoparticles by a solvent emulsification–diffusion technique,” Int. J. Pharm., vol. 257, no. 1, pp. 153–160, May 2003.
[29] F. Q. Hu, et al., "Preparation and characterization of stearic acid nanostructured lipid carriers by solvent diffusion method in an aqueous system,” Colloids Surf. B Biointerfaces, vol.45, no. 3, pp. 167–173, Nov. 2005.
[30] J. E. Kipp, "The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs,” Int. J. Pharm., vol. 284, no. 1–2, pp. 109-22, Oct. 2004.
[31] E. Souto, W. Mehnert, R. Müller, "Polymorphic behaviour of Compritol® 888 ATO as bulk lipid and as SLN and NLC,” J. microencapsul., vol. 23, no. 4, pp. 417-433, June 2006.
[32] W. Sutananta, D. Q. M. Craig, and J. M. Newton, "An evaluation of the mechanisms of drug release from glyceride bases,” J. Pharm. Pharmacol., vol. 47, no. 3, pp. 182-187, March 1995.
[33] P. Costa, and J. M. Sousa Lobo, "Modeling and comparison of dissolution profiles,” Eur. J. Pharm. Sci., vol. 13, no. 2, pp. 123-33, Dec. 2000.